XGN (Exagen) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 24, 2026)


XGN Exagen Inc XGN
58 GF Score
Price $4.52
GF Value $3.00
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Exagen Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Exagen's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

XGN vs FONR, BNR, BDSX: Margin of Safety % (DCF Earnings Based) Comparison

For the Diagnostics & Research subindustry, Exagen's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exagen Margin of Safety % (DCF Earnings Based) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exagen's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Exagen's Margin of Safety % (DCF Earnings Based) falls into.


XGN
58GF Score
Exagen Inc XGN
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Exagen (XGN) Overvalued in 2026?

Based on GuruFocus' analysis, Exagen stock appears to be overvalued. The current stock price of $4.52 is trading 50.7% above its estimated GF Value™ of $3.00. GuruFocus considers Exagen to be Significantly Overvalued.

Key valuation signals for XGN:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $3.00 vs. price of $4.52 (50.7% above fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the XGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Exagen Business Description

Other Exchanges E08A:Germany
Address 1261 Liberty Way, Vista, CA, USA, 92081
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
58GF Score

Get the complete analysis for XGN

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.52
Price
$3.00
GF Value